Key changes to revised formulary section - eye

Deletions
Section 2 Cardiovascular
June 2010
Vasodilator antihypertensive drugs - minoxidil, sodium nitroprusside.
Centrally acting - clonidine
Calcium Channel Blockers - Dihydropyridines - nifedipine
Inotropic Sympathomimetics - dopexamine
Oral anticoagulants - phenindione
Antifibrinolytics - etamsylate
Bile acid sequestrants - colestipol
Dabigatran etexilate (Pradaxa®). Restricted use for the prevention of stroke and
systemic embolism in adult patients with non-valvular atrial fibrillation with one or
more risk factors. Restricted to patients in whom there is poor INR control with
warfarin unrelated to compliance or in patients who are genuinely intolerant of
warfarin/coumarins.
Section 3 Respiratory
June 2011
SABA choice - terbutaline removed. LABAs - Indacaterol moved to restricted list. Cromoglicate and related therapy - no products recommended. Sodium cromoglicate, nedocromil sodium removed. Leukotriene receptor antagonists - zafirlukast removed. Allergen immunotherapy - Omalizumab moved to restricted list. Respiratory stimulants and pulmonary surfactants moved to the restricted list. Section 4 CNS
February 2010
Sibutramine for treatment of obesity. Marketing authorisation suspended due to risk of cardiovascular adverse effects. Instanyl® nasal spray. Preferred nasal spray formulation is PecFent® Section 5 Infections
June 2010
Antipseudomonal penicillins -Tazocin® (replaced with generic name).
Cephalosporins - Cefaclor and cefuroxime for general use in primary care.
Tetracyclines - Minocycline.
Tetracycline
Aminoglycosides - Neomycin
Anti-tuberculous drugs -
Rifabutin
Rimactazid®
Streptomycin
Quinolones - Moxifloxacin
Antifungal drugs - Flucytosine
HIV Infection - Combivir®
Statement stating Famciclovir is not approved for genital herpes. CMV Infection - Foscarnet
Influenza - Amantadine
RSV - Ribavarin
Antimalarials - Primaquine
Pneumocystis Pneumonia - Pentamidine
Enfuviritide. In combination with other anti-retroviral medicinal products for the
treatment of human immunodeficiency virus (HIV-1) infection in adult patients.
Section 6 Endocrine System
April 2010
Vildagliptin (Galvus®). Treatment of type 2 diabetes mellitus in combination with metformin. Replaced by saxagliptin. Rosiglitazone (Avandia®, Avandamet®). Treatment of type 2 diabetes mellitus. Marketing authorisation suspended due to risk of cardiovascular adverse effects. Section 7 Obstetrics, gynaecology and urinary tract disorders
December 2010
Implanon® Contraceptive Implant. Replaced by Nexplanon®. Section 9 Nutrition and Blood
October 2011
Calcichew-D3®, Calfovit®, Calceos® Calcium and vitamin D preparations. Formulary choice for all formulations is Adcal-D3 range. Section 10 Musculoskeletal
October 2011
Coxibs - no longer recommended as formulary choices for any group of patients. Only to be used when at least 2 standard NSAIDs have been ineffective / not tolerated. Topicasl NSAIDs - ketoprofen, Algesal, Movelat, Transvasin. Section 11 Eye
October 2009
Removal of non-specific second line agents i.e. gentamicin, polyfax, propamidine Corticosteroids - Removed statement about prescribing in primary care on acute prescription only and reviewing every 2 months. Mydriatics - Removed homatropine as antimuscarinic choice Beta-blockers - removed carteolol, levobunolol Peri-operative preps. - Removal of flurbiprofen, acetylcholine chloride, apraclonidine. AMD - Removal of pegaptinib Section 12 ENT
March 2012
Fluticasone propionate nasal spray. Triamcinolone nasal spray Azelastine nasal spray Budesonide nasal spray Adcortyl in Orabase Amphoteracin lozenges Section 13 Skin
December 2009
Medium weight emollients - Calmurid, Hydromol cream, Unguentum M Bath additives - Aveeno, Hydromol. Barrier preps. - Epaderm Rosacea Oral choices - Lymecycline, minocycline Camouflagers - Covermark Cocois scalp ointment

Source: http://admin.1fife.org.uk/weborgs/nhs/uploadfiles/publications/c64_DeletionsfromFormulary.pdf